Aploda (Capecitabine) 150mg & 500mg
Capecitabine is a non-cytotoxic fluoropyrimidine carbamate, which functions as an orally administered precursor of the cytotoxic moiety 5-fluorouracil (5-FU). Capecitabine is activated via several enzymatic steps (see section 5.2).
Share Now
Additional Information
Name | Aploda |
Description | Capecitabine is a non-cytotoxic fluoropyrimidine carbamate, which functions as an orally administered precursor of the cytotoxic moiety 5-fluorouracil (5-FU). Capecitabine is activated via several enzymatic steps (see section 5.2). The enzyme involved in the final conversion to 5-FU, thymidine phosphorylase (ThyPase), is found in tumour tissues, but also in normal tissues, albeit usually at lower levels. In human cancer xenograft models capecitabine demonstrated a synergistic effect in combination with docetaxel, which may be related to the upregulation of thymidine phosphorylase by docetaxel. |
Active Ingredient | Capecitabine |
Indication | Adjuvant treatment of patients following surgery of stage III (Dukes’stage C) colon cancer.
|
Strengths | 500mg and 150mg |
Related Products
Related products
Azacitidine (Azadual)
Rated 0 out of 5Levaletrol (Letrozole) 2.5 mg
Rated 0 out of 5Golexin (Goserelin) 3.6mg
Rated 0 out of 5Dacin®(Dacarbazine) – 100 mg, 200 mg
Rated 0 out of 5
Disclaimer
Pharma Solution is the marketing agent and Distributor for the listed products for the Gulf and MENA region. The products are either registered and approved by the respective local health authority or contracted by the MAH to supply to the end users on a named patient basis. Some products such as Orphan drugs, rare diseases medicines are imported based on special import permits and as per need of the Hospitals in compliance with full documentation.